Alnylam Pharmaceuticals (ALNY) , a commercial-stage company, focuses on developing novel therapeutics based on RNAi. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas — genetic medicines, cardio-metabolic disease and hepatic infectious disease. Alnylam currently markets four drugs — Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Onpattro (patisiran).Portfolio of Marketed Drugs Boosts RevenuesAmvuttra, the company’s lead drug, is ...